Navigation Links
Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
Date:2/1/2013

LAKE FOREST, Calif., Feb. 1, 2013 /PRNewswire/ -- TRIMEDYNE, INC. (OTCBB "TMED") reported revenues of $6,080,000 for the fiscal year ended September 30, 2012, a 9% decrease from revenues of $6,656,000 for the prior fiscal year.  The decrease in revenues was largely due to a decrease in sales of Lasers, partially offset by an increase in sales of Fibers, Needles and Tips.

The Company had an operating loss of $1,170,000 for the 2012 fiscal year, compared to an operating loss of $1,522,000 for the prior fiscal year.  Due to economies instituted in the past year, the Company had net loss of $836,000 or $0.05 per share for the fiscal year ended September 30, 2012, as compared to a net loss of $1,486,000 or $0.08 per share for the prior fiscal year.

For the quarter ended September 30, 2012, the Company had revenues of $1,449,000, a 16% decrease from revenues of $1,732,000 for the same quarter of the prior year.  Due to economies instituted in the past year, the Company had an operating loss of $340,000 for the quarter ended September 30, 2012, compared to an operating loss of $683,000 for the same quarter of the prior year.  The Company had a net loss of $314,000 or $0.02 per share for the quarter ended September 30, 2012, versus a net loss of $689,000 or $0.04 per share for the year earlier quarter.

Included in the cost of sales for the fiscal year and quarter ended September 30, 2012, was a charge for excess and obsolete inventory of $225,000.  Without this non-cash charge, the Company's loss from operations for the fiscal year and quarter ended September 30, 2012, would have been $945,000 and $115,000, respectively, and the Company's net loss for the fiscal year and quarter ended September 30, 2012, would have been $611,000 and $89,000, respectively.

The Company ended the 2012 fiscal year with cash and equivalents of $472,000 and receivables and other current assets of $651,000, versus accounts payable and accrued expenses of $501,000.

The Company is aggressively pursuing financing for the seven (7) subsidiaries the Company plans to organize to conduct clinical trials of the Company's breakthrough lasers and optical fiber devices to treat a variety of medical conditions, as described in the Company's Press Release of November 28, 2012.

Trimedyne manufactures proprietary Holmium lasers and patented fiber optic laser devices for vaporizing the prostate to treat BPH, vaporizing spinal disc tissue to treat herniated or ruptured discs and in a variety of other, minimally invasive procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery.  For product, press release, financial, SEC Reports and other information, please visit Trimedyne's website, http://www.trimedyne.com.    

"Safe Harbor" Statement Under  the Private Securities Litigation Reform Act:
Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "expect", "may", "could" and others.  Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's current Form 10-K Report and subsequently filed SEC reports.  There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

CONTACT:

Jeffrey Rudner


(949) 951-3800, Ext. 285


jrudner@trimedyne.com


'/>"/>
SOURCE Trimedyne, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):